ClinicalTrials HQ

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Active, not recruiting · NCT03915184 · Registry updated 2023-12-19
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, carcinoma, cardiovascular disorder, epithelial neoplasm, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseActive, not recruitingPhase 1 / Phase 22023-12-19NCT03915184

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
CARsgen Therapeutics Co., Ltd.20

13 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Colorado Blood Cancer InstituteDenverUnited States178
Dana Farber Cancer CenterBostonUnited States6
Huntsman Cancer CenterSalt Lake CityUnited States2
MayoRochesterUnited States2
Mayo Clinic HospitalPhoenixUnited States41
MD AndersonHoustonUnited States56
Medical College of WisconsinMilwaukeeUnited States483
Methodist HosptialHoustonUnited States1
Moffitt Cancer CenterTampaUnited States523
Princess Margaret HospitalTorontoCanada1
TriStar CMCNashvilleUnited States1
UCSFSan FranciscoUnited States27
UT Southwestern Medical CenterDallasUnited States1